Standout Papers

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer 2012 2026 2016 2021 2.6k
  1. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer (2012)
    Sunil Verma, David Miles et al. New England Journal of Medicine
  2. Evaluating eligibility criteria of oncology trials using real-world data and AI (2021)
    Ruishan Liu, Shemra Rizzo et al. Nature

Immediate Impact

4 by Nobel laureates 18 from Science/Nature 94 standout
Sub-graph 1 of 21

Citing Papers

Artificial intelligence in drug development
2025 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
1 intermediate paper

Works of Michael W. Lu being referenced

Evaluating eligibility criteria of oncology trials using real-world data and AI
2021 StandoutNature
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout

Author Peers

Author Last Decade Papers Cites
Michael W. Lu 2763 981 1541 18 3.5k
Ellie Guardino 3842 1234 2157 30 4.6k
Adam Knott 3085 949 1396 33 4.0k
Steven R. Olsen 3008 849 1372 23 3.9k
Steven Stein 2973 1184 978 20 3.6k
Stephen D. Rubin 2583 1312 791 17 3.9k
Neville Davidson 3634 1151 864 25 4.9k
José Luiz Pedrini 4021 1404 1512 25 4.9k
Robert Ford 2090 1387 896 19 3.6k
Laslo Roman 4232 1285 1324 31 5.0k
Deborah Lindquist 2460 915 792 22 2.9k

All Works

Loading papers...

Rankless by CCL
2026